{
    "Rank": 1005,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT03316586",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "17-324"
                },
                "Organization": {
                    "OrgFullName": "Dana-Farber Cancer Institute",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer",
                "OfficialTitle": "A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "November 2021",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "November 30, 2017",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "August 30, 2019",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "August 30, 2019",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "October 18, 2017",
                "StudyFirstSubmitQCDate": "October 18, 2017",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "October 20, 2017",
                    "StudyFirstPostDateType": "Actual"
                },
                "ResultsFirstSubmitDate": "October 18, 2021",
                "ResultsFirstSubmitQCDate": "November 29, 2021",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "December 28, 2021",
                    "ResultsFirstPostDateType": "Actual"
                },
                "ResultsFirstPostedQCCommentsDateStruct": {
                    "ResultsFirstPostedQCCommentsDate": "November 16, 2021",
                    "ResultsFirstPostedQCCommentsDateType": "Actual"
                },
                "LastUpdateSubmitDate": "November 29, 2021",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "December 28, 2021",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Sara Tolaney",
                    "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
                    "ResponsiblePartyInvestigatorAffiliation": "Dana-Farber Cancer Institute"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Dana-Farber Cancer Institute",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Bristol-Myers Squibb",
                            "CollaboratorClass": "INDUSTRY"
                        },
                        {
                            "CollaboratorName": "Exelixis",
                            "CollaboratorClass": "INDUSTRY"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes",
                "IsFDARegulatedDrug": "Yes",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "This research study is studying a combination of drugs as a possible treatment for metastatic triple-negative breast cancer.\n\nThe drugs involved in this study are:\n\nCabozantinib (XL184)\nNivolumab",
                "DetailedDescription": "This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. \"Investigational\" means that the intervention is being studied.\n\nThe FDA (the U.S. Food and Drug Administration) has not approved the combination of Nivolumab and Cabozantinib as a treatment for any disease.\n\nThe FDA has not approved Cabozantinib for this specific disease but it has been approved for other uses. The FDA (the U.S. Food and Drug Administration) has not approved nivolumab for this specific disease but it has been approved for other uses.\n\nCabozantinib has been used in some phase I studies and information from those other research studies suggests that cabozantinib may help to shrink or stabilize breast cancer.\n\nCancers are recognized by the immune system, and under some circumstances, the immune system may control or even eliminate tumors. An antibody is a natural protein made by the immune system that binds other proteins and molecules to fight infection and its ill effects. Antibodies stimulating the immune system have been developed for treatment of human cancers. Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.\n\nIn this research study, the investigators are looking at how the participant's type of breast cancer responds to the combination of cabozantinib and nivolumab."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Breast Cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "18",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Nivolumab + Cabozantinib",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Nivolumab was administered every 28 days at a dose of 480mg given intravenously over 30 minutes (+/- 10 minutes) using a volumetric pump with 0.2 to 1.2 micron pore size, low protein binding polyethersulfone membrane in-line filter\nCabozantinib was administered orally, once daily for 28 days at a dose of 40 mg.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: Nivolumab",
                                    "Drug: Cabozantinib"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Nivolumab",
                            "InterventionDescription": "Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Nivolumab + Cabozantinib"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Opdivo"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Cabozantinib",
                            "InterventionDescription": "Cabozantinib may help to shrink or stabilize breast cancer",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Nivolumab + Cabozantinib"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Cabometyx"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Overall Response Rate",
                            "PrimaryOutcomeDescription": "Overall response rate (ORR) is defined as the percentage of patients with complete or partial response evaluated by RECIST 1.1. Per RECIST 1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.",
                            "PrimaryOutcomeTimeFrame": "2 years"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Number of Participants With Adverse Events",
                            "SecondaryOutcomeDescription": "Toxicities will be defined according to NCI CTCAE, Version 4.0",
                            "SecondaryOutcomeTimeFrame": "2 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Clinical Benefit Rate",
                            "SecondaryOutcomeDescription": "Clinical Benefit Rate (CBR) will be determined by looking at the number of subjects who have either a complete response, partial response, or stable disease for greater than or equal to 24 weeks, per RECIST 1.1",
                            "SecondaryOutcomeTimeFrame": "2 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Progression Free Survival Rate",
                            "SecondaryOutcomeDescription": "Progression free survival is defined from the study entry to first documented evidence of disease progression by RECIST 1.1 or death of any cause, whichever occurs first. Patients alive with no progression are censored at the last disease assessment.",
                            "SecondaryOutcomeTimeFrame": "5 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Overall Response Rate Per Immune Criteria",
                            "SecondaryOutcomeDescription": "ORR will be determined according to immune-related response criteria (irRC). Per irRC, irComplete Response (irCR) refers to complete disappearance of all target lesions. irPartial Response (irPR) refers to decrease, relative to baseline, of 50% or greater in the sum of the products of the two largest perpendicular diameters of all target and all new measurable target lesions (i.e., Percentage Change in Tumor Burden). ORR per irRC is irCR + irPR.",
                            "SecondaryOutcomeTimeFrame": "2 years"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nParticipants must have histologically or cytologically confirmed invasive breast cancer, with metastatic disease. Participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation.\nEstrogen-receptor and progesterone-receptor expression both <10% by immunohistochemistry (IHC) and human epidermal growth factor receptor 2 (HER2) negative by IHC or non-amplified as determined by the current American Society of Clinical Oncology (ASCO)/CAP (College of American Pathologists) criteria. If patient has more than one histological result, the most recent one has to be considered for inclusion.\nParticipants must have measurable disease by RECIST version 1.1\nParticipants must agree to undergo a research biopsy, if tumor is safely accessible, at baseline and 7-14 days prior to Cycle 3 Day 1. Participants for whom newly-obtained samples cannot be provided (e.g. inaccessible or participant safety concern) may submit an archived specimen.\n\nNote: After the first 6 participants undergo biopsy on cabozantinib, we will review their adverse event profiles to ensure no more than a 20% rate of grade 3 or higher bleeding or wound healing complications occur. If more than 2 patients (>20%) have safety concerns, we will reassess the safety of collecting the research biopsies. Full review of all grade (including grade 1 and 2) may also prompt changes and will be reviewed by the study team. Exelixis may be consulted if necessary.\n\nPrior chemotherapy: Participants may have received 0-3 prior chemotherapeutic regimens for metastatic breast cancer and must have been off treatment with chemotherapy for at least 14 days prior to registration. Participants should also be adequately recovered from acute toxicities of prior treatment.\nPrior biologic therapy: Patients must have discontinued all biologic therapy at least 14 days prior to registration.\n\nPrior radiation therapy: Patients may have received prior radiation therapy in either the metastatic or early-stage setting. Radiation therapy must be completed per the following timelines:\n\nRadiotherapy to the thoracic cavity or abdomen within 4 weeks prior to registration.\nRadiotherapy to bone lesions within 2 weeks prior to registration.\nRadiotherapy to any other site within 4 weeks prior to registration.\nIn all cases, there must be complete recovery and no ongoing complications from prior radiotherapy.\nThe subject is \u226518 years old.\nECOG (Eastern Cooperative Oncology Group) performance status \u22641(Karnofsky \u226560%, see Appendix A)\n\nParticipants must have normal organ and marrow function as defined below:\n\nabsolute neutrophil count \u22651,000/microliter (mcL)\nplatelets \u2265100,000/mcL\nhemoglobin \u2265 9 g/dl\ntotal bilirubin \u22641.5 \u00d7 institutional upper limit of normal (ULN) (or 2.0 x ULN in patients with documented Gilbert's Syndrome)\nAspartate aminotransferase (AST) / Alanine transaminase (ALT) \u22642.5 \u00d7 institutional ULN or \u2264 3 \u00d7 institutional ULN for participants with documented liver metastases\ncreatinine <1.5 \u00d7institutional ULN OR creatinine clearance \u226540 mL/min (using Cockcroft-Gault formula) for participants with creatinine levels above institutional ULN.\nUrine protein/creatinine ratio (UPCR) \u22641\nFemale subjects of childbearing potential must have a negative pregnancy test at screening\nChildbearing potential is defined as: participants who have not reached a postmenopausal state (\u2265 12 continuous months of amenorrhea with no identified cause other than menopause) and has not undergone surgical sterilization (removal of ovaries and/or uterus).\nFemale and male participants of childbearing potential must agree to use an adequate method of contraception. Contraception is required starting with the first dose of study medication through 150 days (5 months) after the last dose of study medication . Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, established and proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\nParticipants on bisphosphonates may continue receiving bisphosphonate therapy during study treatment.\nThe participant is capable of understanding and complying with the protocol and has signed the informed consent document\n\nExclusion Criteria:\n\nMajor surgery within 12 weeks before the first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment. Minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment. No clinically relevant ongoing complications from prior surgery are not eligible.\nThe participant has tumor in contact with, invading, or encasing major blood vessels or radiographic evidence of significant cavitary pulmonary lesions.\nThe subject has pathologic evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib;\nConcurrent administration of other anti-cancer therapy within 14 days of starting protocol therapy and during the course of this study.\nThe participant has received another investigational agent within 14 days of the first dose of study drug.\nThe participant has received a prior c-Met inhibitor\nHas received prior therapy with an anti-programmed cell death-1 (PD-1), anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including pembrolizumab, ipilimumab, and any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)\nKnown brain metastases that are untreated, symptomatic, or require therapy to control symptoms. Participants with a history of treated central nervous system (CNS) metastases are eligible. Treated brain metastases are defined as those having no evidence of progression for \u2265 1 month after treatment, and no ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (magnetic resonance imaging or CT scan) completed during screening. Any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for \u22652 weeks prior to registration. Treatment for brain metastases may include whole brain radiotherapy, radiosurgery, or a combination as deemed appropriate by the treating physician. Participants with CNS metastases treated by neurosurgical resection or brain biopsy performed within 2 months before day 1 will be excluded.\n\nThe subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\nCardiovascular disorders including:\nCongestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening;\nConcurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment;\nAny history of congenital long QT syndrome;\nAny of the following within 6 months before the first dose of study treatment:\nunstable angina pectoris;\nclinically-significant cardiac arrhythmias;\nstroke (including transient ischemic attack (TIA), or other ischemic event);\nmyocardial infarction;\nGI disorders particularly those associated with a high risk of perforation or fistula formation including:\nTumors invading the GI tract, active peptic ulcer disease, active inflammatory bowel disease (eg, Crohn's disease), active diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction\nAbdominal fistula, GI perforation, bowel obstruction, intra-abdominal abscess within 6 months before randomization, Note: Complete healing of an intra-abdominal abscess must be confirmed prior to randomization\nOther clinically significant disorders that would preclude safe study participation;\nCorrected Fridericia's QT interval (QTcF) interval >500 msec Note: Three ECGs must be performed for eligibility determination. If the average of these three consecutive results for QTcF is \u2264 500 msec, the subject meets eligibility in this regard.\nThromboembolic events requiring therapeutic anticoagulation. Concomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors), platelet inhibitors (eg, clopidogrel) are prohibited.\n\nNote: Low-dose aspirin for cardioprotection (per local applicable guidelines) and low-dose low molecular weight heparin (LMWH) are permitted (in subjects who are on a stable dose of LMWH for at least 6 weeks before the first dose of study treatment, and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor).\n\nNote: Subjects with a venous filter (eg vena cava filter) are not eligible for this study).\n\nIndividuals with a history of different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years or are deemed by the investigator to be at low risk for recurrence of that malignancy.\nParticipant has an active infection requiring IV antibiotics\nPatient has a medical condition that requires chronic systemic steroid therapy or on any other form of immunosuppressive medication. For example, participants with autoimmune disease that requires systemic steroids or immunosuppression agents should be excluded. Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\nThe participant is known to be positive for the human immunodeficiency virus (HIV), HepBsAg, or Hepatitis C virus (HCV) RNA. HIV-positive participants on combination antiretroviral therapy are ineligible.\nKnown hypersensitivity to any of the components of cabozantinib or nivolumab.\nThe participant has received a live vaccine within 28 days prior to the first dose of trial treatment and while participating in the trial. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, bacille Calmette-Guerin (BCG), and typhoid vaccine. The use of the inactivated seasonal influenza vaccine (Fluzone\u00ae) is allowed.\n\nThe subject has experienced any of the following:\n\nClinically significant gastrointestinal bleeding within 6 months before the first dose of study treatment\nClinically significant hemoptysis within 3 months of the first dose of study treatment\nAny other signs indicative of pulmonary hemorrhage within 3 months before the start of study treatment\nThe participant is unable to swallow oral dosage forms.\nThe participant is pregnant or breastfeeding",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Sara Tolaney, MD, MPH",
                            "OverallOfficialAffiliation": "Dana-Farber Cancer Institute",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Dana-Farber Cancer Institute",
                            "LocationCity": "Boston",
                            "LocationState": "Massachusetts",
                            "LocationZip": "02215",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No"
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "Nivolumab + Cabozantinib",
                            "FlowGroupDescription": "Nivolumab was administered every 28 days at a dose of 480mg given intravenously over 30 minutes (+/- 10 minutes) using a volumetric pump with 0.2 to 1.2 micron pore size, low protein binding polyethersulfone membrane in-line filter\nCabozantinib was administered orally, once daily for 28 days at a dose of 40 mg.\n\nNivolumab: Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.\n\nCabozantinib: Cabozantinib may help to shrink or stabilize breast cancer"
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "18"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "FlowDropWithdrawList": {
                                "FlowDropWithdraw": [
                                    {
                                        "FlowDropWithdrawType": "Adverse Event",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "2"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Physician Decision",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "3"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Lack of Efficacy",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "10"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "still on treatment",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Patient needed radiation therapy",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Physician Decision to send patient for breast surgery",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "Nivolumab + Cabozantinib",
                            "BaselineGroupDescription": "Nivolumab was administered every 28 days at a dose of 480mg given intravenously over 30 minutes (+/- 10 minutes) using a volumetric pump with 0.2 to 1.2 micron pore size, low protein binding polyethersulfone membrane in-line filter\nCabozantinib was administered orally, once daily for 28 days at a dose of 40 mg.\n\nNivolumab: Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.\n\nCabozantinib: Cabozantinib may help to shrink or stabilize breast cancer"
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "18"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Median",
                            "BaselineMeasureDispersionType": "Full Range",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "58",
                                                                "BaselineMeasurementLowerLimit": "41",
                                                                "BaselineMeasurementUpperLimit": "71"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "18"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Race (NIH/OMB)",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Asian",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Black or African American",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "White",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "15"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "More than one race",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown or Not Reported",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "18"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "ECOG",
                            "BaselineMeasureDescription": "The ECOG (Eastern Cooperative Oncology Group) Scale of Performance Status describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.). This is a numbering scale of 0 to 5. The higher the number, the worse the performance status. Zero (0) refers to being full active. 5 is dead.",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "0",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "18"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "1",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Stage at initial Diagnosis",
                            "BaselineMeasureDescription": "The stage of breast cancer is determined by the cancer's characteristics such as how large it is and whether or not it has hormone receptors. This is usually expressed as a number on a scale of 0 through IV, with stage 0 describing non-invasive cancers that remain within their original location and stage IV describing invasive cancers that have spread outside the breast to other parts of the body.",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "I",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "3"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "II",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "6"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "III",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "IV",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "5"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Disease free interval",
                            "BaselineMeasureDescription": "It is measured from the primary diagnosis to the diagnosis of metastatic cancer.",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "De novo",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "5"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "<=2 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "4"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": ">2 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "5"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Date missing",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "4"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sites of disease -- lung pleural",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "6"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sites of disease -- liver",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "7"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sites of disease -- bone",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "8"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sites of disease -- Breast/chest wall",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "7"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sites of disease -- Lymph node",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "11"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sites of disease -- Soft tissue",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "3"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Adjuvant or neoadjuvant hormonal therapy",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Adjuvant or or neoadjuvant anthracycline",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "12"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Adjuvant or neoadjuvant taxane",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "12"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Lines of chemotherapy for metastasis or recurrence",
                            "BaselineMeasureParamType": "Median",
                            "BaselineMeasureDispersionType": "Full Range",
                            "BaselineMeasureUnitOfMeasure": "line",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "1",
                                                                "BaselineMeasurementLowerLimit": "0",
                                                                "BaselineMeasurementUpperLimit": "3"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Lines of chemotherapy for metastasis or recurrence",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "0",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "5"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "1",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "6"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "2",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "5"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "3",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Prior metastatic chemotherapy -- Anthracycline",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "4"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Prior metastatic chemotherapy -- Taxane",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "5"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Prior metastatic chemotherapy -- Platinum",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "11"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Prior metastatic chemotherapy -- Capecitabine",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Prior metastatic chemotherapy -- Eribulin",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Prior metastatic chemotherapy -- Other chemotherapy",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "6"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "ER, PR, and HER2 status at study entry",
                            "BaselineMeasureDescription": "ER: Estrogen receptors PR: progesterone receptors",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "ER and/or PR-positive (\u226410%), HER2-negative",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "ER and PR negative, HER2-negative",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "16"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "PD-L1 positive cells",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "TILs in metastatic samples",
                            "BaselineMeasureDescription": "TILs: tumor-infiltrating lymphocytes",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "3"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Overall Response Rate",
                            "OutcomeMeasureDescription": "Overall response rate (ORR) is defined as the percentage of patients with complete or partial response evaluated by RECIST 1.1. Per RECIST 1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.",
                            "OutcomeMeasurePopulationDescription": "For this Phase II trial, the efficacy evaluable population is a modified intent-to-treat (ITT) population. The modified ITT population consists of all patients who initiate protocol therapy, even if there are major protocol therapy deviations.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "2 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Nivolumab + Cabozantinib",
                                        "OutcomeGroupDescription": "Nivolumab was administered every 28 days at a dose of 480mg given intravenously over 30 minutes (+/- 10 minutes) using a volumetric pump with 0.2 to 1.2 micron pore size, low protein binding polyethersulfone membrane in-line filter\nCabozantinib was administered orally, once daily for 28 days at a dose of 40 mg.\n\nNivolumab: Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.\n\nCabozantinib: Cabozantinib may help to shrink or stabilize breast cancer"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "18"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Number of Participants With Adverse Events",
                            "OutcomeMeasureDescription": "Toxicities will be defined according to NCI CTCAE, Version 4.0",
                            "OutcomeMeasurePopulationDescription": "For this Phase II trial, the efficacy evaluable population is a modified intent-to-treat (ITT) population. The modified ITT population consists of all patients who initiate protocol therapy, even if there are major protocol therapy deviations.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "2 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Nivolumab + Cabozantinib",
                                        "OutcomeGroupDescription": "Nivolumab was administered every 28 days at a dose of 480mg given intravenously over 30 minutes (+/- 10 minutes) using a volumetric pump with 0.2 to 1.2 micron pore size, low protein binding polyethersulfone membrane in-line filter\nCabozantinib was administered orally, once daily for 28 days at a dose of 40 mg.\n\nNivolumab: Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.\n\nCabozantinib: Cabozantinib may help to shrink or stabilize breast cancer"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "18"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "18"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Clinical Benefit Rate",
                            "OutcomeMeasureDescription": "Clinical Benefit Rate (CBR) will be determined by looking at the number of subjects who have either a complete response, partial response, or stable disease for greater than or equal to 24 weeks, per RECIST 1.1",
                            "OutcomeMeasurePopulationDescription": "For this Phase II trial, the efficacy evaluable population is a modified intent-to-treat (ITT) population. The modified ITT population consists of all patients who initiate protocol therapy, even if there are major protocol therapy deviations.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "2 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Nivolumab + Cabozantinib",
                                        "OutcomeGroupDescription": "Nivolumab was administered every 28 days at a dose of 480mg given intravenously over 30 minutes (+/- 10 minutes) using a volumetric pump with 0.2 to 1.2 micron pore size, low protein binding polyethersulfone membrane in-line filter\nCabozantinib was administered orally, once daily for 28 days at a dose of 40 mg.\n\nNivolumab: Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.\n\nCabozantinib: Cabozantinib may help to shrink or stabilize breast cancer"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "18"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "3"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Progression Free Survival Rate",
                            "OutcomeMeasureDescription": "Progression free survival is defined from the study entry to first documented evidence of disease progression by RECIST 1.1 or death of any cause, whichever occurs first. Patients alive with no progression are censored at the last disease assessment.",
                            "OutcomeMeasurePopulationDescription": "For this Phase II trial, the efficacy evaluable population is a modified intent-to-treat (ITT) population. The modified ITT population consists of all patients who initiate protocol therapy, even if there are major protocol therapy deviations.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Median",
                            "OutcomeMeasureDispersionType": "95% Confidence Interval",
                            "OutcomeMeasureUnitOfMeasure": "months",
                            "OutcomeMeasureTimeFrame": "5 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Nivolumab + Cabozantinib",
                                        "OutcomeGroupDescription": "Nivolumab was administered every 28 days at a dose of 480mg given intravenously over 30 minutes (+/- 10 minutes) using a volumetric pump with 0.2 to 1.2 micron pore size, low protein binding polyethersulfone membrane in-line filter\nCabozantinib was administered orally, once daily for 28 days at a dose of 40 mg.\n\nNivolumab: Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.\n\nCabozantinib: Cabozantinib may help to shrink or stabilize breast cancer"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "18"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "3.6",
                                                                "OutcomeMeasurementLowerLimit": "1.9",
                                                                "OutcomeMeasurementUpperLimit": "6.9"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Overall Response Rate Per Immune Criteria",
                            "OutcomeMeasureDescription": "ORR will be determined according to immune-related response criteria (irRC). Per irRC, irComplete Response (irCR) refers to complete disappearance of all target lesions. irPartial Response (irPR) refers to decrease, relative to baseline, of 50% or greater in the sum of the products of the two largest perpendicular diameters of all target and all new measurable target lesions (i.e., Percentage Change in Tumor Burden). ORR per irRC is irCR + irPR.",
                            "OutcomeMeasurePopulationDescription": "For this Phase II trial, the efficacy evaluable population is a modified intent-to-treat (ITT) population. The modified ITT population consists of all patients who initiate protocol therapy, even if there are major protocol therapy deviations.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "2 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Nivolumab + Cabozantinib",
                                        "OutcomeGroupDescription": "Nivolumab was administered every 28 days at a dose of 480mg given intravenously over 30 minutes (+/- 10 minutes) using a volumetric pump with 0.2 to 1.2 micron pore size, low protein binding polyethersulfone membrane in-line filter\nCabozantinib was administered orally, once daily for 28 days at a dose of 40 mg.\n\nNivolumab: Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.\n\nCabozantinib: Cabozantinib may help to shrink or stabilize breast cancer"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "18"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeCategoryTitle": "irPR",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "irSD",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "14"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "irPD",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "not evaluable",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "5",
                "EventsTimeFrame": "AE data were collected every cycle from the time of the first dose of the study treatment, through the end of the treatment. Vital status was followed even after patients were off treatment. AEs, including overall mortality, were observed up to 60 months.",
                "EventsDescription": "Serious AEs (SAE) were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher. All remaining AEs are classified as Other AEs (OAE) including grade 3 or higher events with treatment-attribution of unlikely and unrelated plus all grade 1 and 2 events. Maximum grade toxicity by type was then calculated within SAE and OAE datasets. No further data is available to specify classification of other beyond the general term.",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "Nivolumab + Cabozantinib",
                            "EventGroupDescription": "Nivolumab was administered every 28 days at a dose of 480mg given intravenously over 30 minutes (+/- 10 minutes) using a volumetric pump with 0.2 to 1.2 micron pore size, low protein binding polyethersulfone membrane in-line filter\nCabozantinib was administered orally, once daily for 28 days at a dose of 40 mg.\n\nNivolumab: Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.\n\nCabozantinib: Cabozantinib may help to shrink or stabilize breast cancer",
                            "EventGroupDeathsNumAffected": "3",
                            "EventGroupDeathsNumAtRisk": "18",
                            "EventGroupSeriousNumAffected": "13",
                            "EventGroupSeriousNumAtRisk": "18",
                            "EventGroupOtherNumAffected": "17",
                            "EventGroupOtherNumAtRisk": "18"
                        }
                    ]
                },
                "SeriousEventList": {
                    "SeriousEvent": [
                        {
                            "SeriousEventTerm": "Anemia",
                            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Endocrine disorders - Other, specify",
                            "SeriousEventOrganSystem": "Endocrine disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Small intestinal perforation",
                            "SeriousEventOrganSystem": "Gastrointestinal disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Edema trunk",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Fatigue",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "2",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Appendicitis",
                            "SeriousEventOrganSystem": "Infections and infestations",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Alanine aminotransferase increased",
                            "SeriousEventOrganSystem": "Investigations",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "2",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Aspartate aminotransferase increased",
                            "SeriousEventOrganSystem": "Investigations",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "3",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Dehydration",
                            "SeriousEventOrganSystem": "Metabolism and nutrition disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Hypokalemia",
                            "SeriousEventOrganSystem": "Metabolism and nutrition disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Back pain",
                            "SeriousEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Syncope",
                            "SeriousEventOrganSystem": "Nervous system disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Dyspnea",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Hypoxia",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Pneumonitis",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Palmar-plantar erythrodysesthesia syndrome",
                            "SeriousEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "3",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Hypertension",
                            "SeriousEventOrganSystem": "Vascular disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "2",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Thromboembolic event",
                            "SeriousEventOrganSystem": "Vascular disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "2",
                                        "SeriousEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "Anemia",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Lymph node pain",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Palpitations",
                            "OtherEventOrganSystem": "Cardiac disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Endocrine disorders - Other, specify",
                            "OtherEventOrganSystem": "Endocrine disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hyperthyroidism",
                            "OtherEventOrganSystem": "Endocrine disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypothyroidism",
                            "OtherEventOrganSystem": "Endocrine disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Abdominal pain",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Constipation",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Diarrhea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dry mouth",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dyspepsia",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dysphagia",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Flatulence",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Gastroesophageal reflux disease",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Mucositis oral",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Nausea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Oral pain",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Vomiting",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Death NOS",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Edema face",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Edema limbs",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Edema trunk",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fatigue",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Allergic reaction",
                            "OtherEventOrganSystem": "Immune system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Infections and infestations - Other, specify",
                            "OtherEventOrganSystem": "Infections and infestations",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Skin infection",
                            "OtherEventOrganSystem": "Infections and infestations",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Upper respiratory infection",
                            "OtherEventOrganSystem": "Infections and infestations",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Spinal fracture",
                            "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Wound complication",
                            "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Alanine aminotransferase increased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Aspartate aminotransferase increased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Creatinine increased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Neutrophil count decreased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Platelet count decreased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Weight loss",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Anorexia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dehydration",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hyponatremia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Back pain",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Chest wall pain",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Generalized muscle weakness",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Muscle weakness lower limb",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Musculoskeletal and connective tissue disorder - Other, specify",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Myalgia",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Neck pain",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dysgeusia",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Headache",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Peripheral sensory neuropathy",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Presyncope",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Anxiety",
                            "OtherEventOrganSystem": "Psychiatric disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Depression",
                            "OtherEventOrganSystem": "Psychiatric disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Chronic kidney disease",
                            "OtherEventOrganSystem": "Renal and urinary disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Allergic rhinitis",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Cough",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dyspnea",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypoxia",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pleural effusion",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Respiratory, thoracic and mediastinal disorders - Other, specify",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Sore throat",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Voice alteration",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Alopecia",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dry skin",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Palmar-plantar erythrodysesthesia syndrome",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pruritus",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Rash maculo-papular",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypertension",
                            "OtherEventOrganSystem": "Vascular disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Thromboembolic event",
                            "OtherEventOrganSystem": "Vascular disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "18"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "Yes"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Sara Tolaney, MD, MPH",
                    "PointOfContactOrganization": "Dana-Farber Cancer Institute",
                    "PointOfContactEMail": "Sara_Tolaney@dfci.harvard.edu",
                    "PointOfContactPhone": "617-632-2335"
                }
            }
        },
        "DocumentSection": {
            "LargeDocumentModule": {
                "LargeDocList": {
                    "LargeDoc": [
                        {
                            "LargeDocTypeAbbrev": "Prot_SAP",
                            "LargeDocHasProtocol": "Yes",
                            "LargeDocHasSAP": "Yes",
                            "LargeDocHasICF": "No",
                            "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
                            "LargeDocDate": "April 9, 2019",
                            "LargeDocUploadDate": "10/18/2021 11:03",
                            "LargeDocFilename": "Prot_SAP_000.pdf"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023",
                "SubmissionTracking": {}
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000064726",
                            "ConditionMeshTerm": "Triple Negative Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M30063",
                            "ConditionBrowseLeafName": "Triple Negative Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Triple Negative Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000077594",
                            "InterventionMeshTerm": "Nivolumab"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000074322",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Immunological"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000082082",
                            "InterventionAncestorTerm": "Immune Checkpoint Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M1854",
                            "InterventionBrowseLeafName": "Nivolumab",
                            "InterventionBrowseLeafAsFound": "Technique",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M9874",
                            "InterventionBrowseLeafName": "Immunoglobulins",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3915",
                            "InterventionBrowseLeafName": "Antibodies",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M1346",
                            "InterventionBrowseLeafName": "Antineoplastic Agents, Immunological",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M2343",
                            "InterventionBrowseLeafName": "Immune Checkpoint Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}